Published in BMC Womens Health on March 23, 2013
Osteoporosis - a current view of pharmacological prevention and treatment. Drug Des Devel Ther (2013) 1.29
Management of osteoporosis of the oldest old. Osteoporos Int (2014) 0.87
Antiosteoporosis effect of radix scutellariae extract on density and microstructure of long bones in tail-suspended sprague-dawley rats. Evid Based Complement Alternat Med (2013) 0.75
Fracture Preventing Effects of Maxmarvil® Tablets (Alendronate 5 mg + Calcitriol 0.5 µg) in Patients with Osteoporosis. J Bone Metab (2017) 0.75
Comparison of the prescribing pattern of bisphosphonate and raloxifene in Korean women with osteoporosis: from a national health insurance claims database. PLoS One (2015) 0.75
Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res (2007) 14.84
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet (1996) 13.20
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA (1999) 11.23
A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003. Stat Med (2008) 11.16
FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int (2008) 8.75
The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone (1995) 5.76
A comparison of propensity score methods: a case-study estimating the effectiveness of post-AMI statin use. Stat Med (2006) 3.87
Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases. Med Care (2007) 3.53
Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. Ann Intern Med (2008) 2.40
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat (2001) 2.26
Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab (2002) 1.82
Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br J Cancer (2010) 1.61
Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab (2002) 1.59
Direct healthcare costs of hip, vertebral, and non-hip, non-vertebral fractures. Bone (2009) 1.22
"Pathologic" fractures: should these be included in epidemiologic studies of osteoporotic fractures? Osteoporos Int (2009) 1.16
Effectiveness of bisphosphonate therapy in a community setting. Bone (2008) 1.01
Characteristics of patients initiating raloxifene compared to those initiating bisphosphonates. BMC Womens Health (2008) 0.99
Relationship between duration of compliant bisphosphonate use and the risk of osteoporotic fractures . Curr Med Res Opin (2008) 0.95
Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass. Bone (2006) 0.94
Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes (2011) 3.25
Patterns and correlates of linkage to appropriate HIV care after HIV diagnosis in the US Medicaid population. Sex Transm Dis (2013) 2.92
Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum (2009) 2.16
Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. J Am Geriatr Soc (2006) 1.96
Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res (2006) 1.58
Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy. Bull NYU Hosp Jt Dis (2008) 1.48
Reduced risk of back pain following teriparatide treatment: a meta-analysis. Osteoporos Int (2005) 1.36
Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J Clin Endocrinol Metab (2009) 1.35
Myocardial infarction following coronary artery bypass graft surgery increases healthcare resource utilization. Crit Care Med (2007) 1.35
Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res (2005) 1.34
Direct and indirect costs of non-vertebral fracture patients with osteoporosis in the US. Pharmacoeconomics (2010) 1.27
A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res (2015) 1.23
Tibia shaft fractures: costly burden of nonunions. BMC Musculoskelet Disord (2013) 1.23
Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States. Adv Ther (2014) 1.22
A multi-worksite analysis of the relationships among body mass index, medical utilization, and worker productivity. J Occup Environ Med (2010) 1.20
Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. J Clin Endocrinol Metab (2004) 1.15
Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene. J Bone Miner Res (2013) 1.14
Osteosarcoma and teriparatide? J Bone Miner Res (2007) 1.14
The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Curr Med Res Opin (2005) 1.11
Preventive services and health behaviors among people with spinal cord injury. J Spinal Cord Med (2005) 1.09
The direct and indirect cost burden of acute coronary syndrome. J Occup Environ Med (2011) 1.08
Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. J Bone Miner Res (2010) 1.08
Impact of cisapride label changes on codispensing of contraindicated medications. Pharmacoepidemiol Drug Saf (2003) 1.04
Teriparatide vertebral fracture risk reduction determined by quantitative and qualitative radiographic assessment. Curr Med Res Opin (2009) 1.02
Vertebral fracture status and the World Health Organization risk factors for predicting osteoporotic fracture risk. J Bone Miner Res (2009) 1.00
Prognostic utility of a semiquantitative spinal deformity index. Bone (2005) 0.99
Economic costs of obesity to self-insured employers. J Occup Environ Med (2008) 0.99
Risk of infections in rheumatoid arthritis patients switching from anti-TNF agents to rituximab, abatacept, or another anti-TNF agent, a retrospective administrative claims analysis. Semin Arthritis Rheum (2013) 0.98
PINP as an aid for monitoring patients treated with teriparatide. Bone (2010) 0.98
Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin (2006) 0.97
Oseltamivir and the risk of influenza-related complications and hospitalizations in patients with diabetes. Clin Ther (2007) 0.96
Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide. J Clin Endocrinol Metab (2007) 0.91
Cost burden of second fracture in the US health system. Bone (2011) 0.91
First fractures among postmenopausal women with osteoporosis. J Bone Miner Metab (2010) 0.89
Economic burden associated with adverse events in patients with metastatic melanoma. J Manag Care Spec Pharm (2015) 0.88
Healthcare costs within a year of respiratory syncytial virus among Medicaid infants. Pediatr Pulmonol (2010) 0.88
Direct health care costs of patients with type 2 diabetes within a privately insured employed population, 2000 and 2005. J Occup Environ Med (2009) 0.88
Changes in vitamin D metabolites during teriparatide treatment. Bone (2012) 0.88
Association between prescription cost sharing and adherence to initial combination antiretroviral therapy in commercially insured antiretroviral-naïve patients with HIV. J Manag Care Pharm (2012) 0.86
Respiratory outcomes, utilization and costs 12 months following a respiratory syncytial virus diagnosis among commercially insured late-preterm infants. Curr Med Res Opin (2010) 0.86
Longterm reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendronate. J Rheumatol (2005) 0.85
Capecitabine treatment patterns in patients with gastroesophageal cancer in the United States. World J Gastroenterol (2009) 0.84
Effect of early clopidogrel discontinuation on rehospitalization in acute coronary syndrome: results from two distinct patient populations. Am J Health Syst Pharm (2011) 0.84
Reduction in vertebral fracture risk in teriparatide-treated postmenopausal women as assessed by spinal deformity index. Bone (2005) 0.84
Retrospective database study to assess the economic impact of hip fracture in the United Kingdom. J Med Econ (2014) 0.83
Predictors of initiating rapid-acting insulin analog using vial/syringe, prefilled pen, and reusable pen devices in patients with type 2 diabetes. J Diabetes Sci Technol (2010) 0.82
Antiresorptive treatment of postmenopausal osteoporosis: review of randomized clinical studies and rationale for the Evista alendronate comparison (EVA) trial. Curr Med Res Opin (2004) 0.82
Costs associated with capecitabine or 5-fluorouracil monotherapy after surgical resection in patients with colorectal cancer. Oncology (2009) 0.81
Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiency. J Clin Endocrinol Metab (2007) 0.81
Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. Bone (2010) 0.81
Respiratory-related medical expenditure and inpatient utilisation among COPD patients receiving long-acting bronchodilator therapy. J Med Econ (2011) 0.81
Association of RSV lower respiratory tract infection and subsequent healthcare use and costs: a Medicaid claims analysis in early-preterm, late-preterm, and full-term infants. J Med Econ (2011) 0.80
Long-term raloxifene for postmenopausal osteoporosis. Curr Med Res Opin (2011) 0.80
Genetically determined angiotensin converting enzyme level and myocardial tolerance to ischemia. FASEB J (2010) 0.80
Cost comparison of drug-drug and drug-condition interactions in patients with painful diabetic peripheral neuropathy treated with pregabalin versus duloxetine. Am J Health Syst Pharm (2013) 0.80
Employees' willingness to pay to prevent influenza. Am J Manag Care (2010) 0.80
Attending work while sick: implication of flexible sick leave policies. J Occup Environ Med (2010) 0.79
The influence of oseltamivir treatment on the risk of stroke after influenza infection. Cardiology (2008) 0.78
Can bundled payment improve quality and efficiency of care for patients with hip fractures? J Aging Soc Policy (2015) 0.78
Comparative incidence and health care costs of medically attended adverse effects among U.S. Medicaid HIV patients on atazanavir- or darunavir-based antiretroviral therapy. Value Health (2013) 0.78
Comments on Initial experience with teriparatide in the United States. Curr Med Res Opin (2006) 0.77
Characteristics of hip fracture patients with and without muscle atrophy/weakness: predictors of negative economic outcomes. J Med Econ (2014) 0.77
STD program activity in state policy processes, 1995 and 2000. Sex Transm Dis (2003) 0.76
Agreement between Internet-based self- and proxy-reported health care resource utilization and administrative health care claims. Value Health (2012) 0.76
Benefits and risks of raloxifene by vertebral fracture status. Curr Med Res Opin (2010) 0.76
Teriparatide, osteoporosis, calcium, and vitamin D. N Engl J Med (2005) 0.75
Commentary on Mobley and Others: importance of assumptions about VTE mortality in modeling the cost-effectiveness of osteoporosis therapies. Med Decis Making (2006) 0.75
State agency policy and program coordination in response to the co-occurrence of HIV, chemical dependency, and mental illness. Public Health Rep (2003) 0.75
Potential drug-drug and drug-condition interactions among fibromyalgia patients initiating pregabalin or duloxetine: prevalence and health care expenditure impact. Pain Med (2014) 0.75
Clinical and economic characteristics of total hip replacement patients with high health care costs and high health care use. Am J Phys Med Rehabil (2015) 0.75
Treatment patterns and survival in metastatic breast cancer patients by tumor characteristics. Curr Med Res Opin (2015) 0.75
Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results From a Phase III Clinical Trial and Long-term Extension. Acta Derm Venereol (2017) 0.75
Effects of a Medicaid prior authorization policy for pregabalin. Am J Manag Care (2009) 0.75
Comparison between guideline-preferred and nonpreferred first-line HIV antiretroviral therapy. Am J Manag Care (2014) 0.75